Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma

British Journal of Cancer

Volumn 75, Issue 3, 1997, Pages 388-395

  Cantero, D ^a   Friess, H ^a   Deflorin, J ^a   Zimmermann, A ^b   Brundler M A ^b   Riesle, E ^a   Korc, M ^c   Buchler M W ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immunohistochemistry; Northern blot analysis; Pancreatic cancer; Urokinase plasminogen activator (uPA); Urokinase plasminogen activator receptor (uPAR)

Indexed keywords

MEMBRANE RECEPTOR; MESSENGER RNA; SERINE PROTEINASE; UROKINASE;

ADOLESCENT; ADULT; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NORTHERN BLOTTING; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURGICAL MORTALITY;

EID: 0031015122     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.63     Document Type: Article

References (47)

1. Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D and Rabbani SA (1994) Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54: 2372-2377
2. Bianchi E, Cohen R, Thor AT, Todd RF, Mizukami IF, Lawrence DA, Ljung BM, Shuman MA and Smith HS (1994) The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 54: 861-866
3. Blasi F, Vassalli J and Dano K (1987) Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol 104: 801-804
4. Bornman PC and Krige JEJ (1994) Prognosis in carcinoma of the pancreas. Dig Surg 11: 342-345
5. Carriero M, Franco P, Del Vecchio S, Massa O, Botti G, D'Aiuto G, Stoppelli MP and Salvatore M (1994) Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res 54: 5445-5454
6. Chomczynski P and Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159
7. Chucholowski N, Schmitt P, Rettenberger P, Schüren E, Moniwa N, Goretzki L, Wilhelm O, Weidle U, Jänicke F and Graeff H (1992) Flow cytofluorometric analysis of the urokinase receptor (uPAR) on tumour cells by fluorescent uPA-ligand or monoclonal antibody 3936. Fibrinolysis 6: 95-102
8. Collen D (1980) On the regulation and control of fibrinolysis. Thromb Haemostas 43: 77-89
9. Dano K, Andreasen PA, Gröndahl-Hansen J, Kristensen P, Nielsen LS and Skriver L (1985) Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139-266
10. Dano K, Behrendt N, Ellis V, Ericksen J, Hoyer-Hansen G, Kristenesen P, Lund LR, Nielsen BS, Ploug M, Pyke C, Ronne E and Blasi F (1992) The role of u-PA and its receptor in tissue remodeling and tumour invasion. Fibrinolysis 6: 10
11. Del Vecchio S, Stopelli MP, Carriero MV, Fonti R, Massa O, Li PY, Botti G, Cerra M, D'aiuto G, Esposito G and Salvatore M (1993) Human urokinase receptor concentration in malignant and benign breast tumours by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res 53: 3198-3206
12. Duggan C, Maguire T, McDermott H, O'Higgins N, Fennelly JJ and Duffy MJ (1995) Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 61: 597-600
13. Ebert M, Yokoyama M, Kobrin MS, Friess H, Lopez M, Büchler MW, Johnson GR and Korc M (1994a) Induction and expression of amphiregulin in human pancreatic cancer. Cancer Res 54: 3959-3962
14. Ebert M, Yokoyama M, Friess H, Büchler MW and Korc M (1994b) Coexpression of the c-met protooncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res 54: 5775-5778
15. Ellis V, Scully MF and Kakkar VV (1989) Plasminogen activation initiated by single-chain urokinase-type plasminogen activator: potentiation by U937 cells. J Biol Chem 264: 2185-2188
16. Estreicher A, Mühlhauser J, Carpentier JL, Orci L and Vasalli JD (1990) The receptor for urokinase-type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 111: 783-792
17. Fazioli F and Blasi F (1994) Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharmacol Sci 15: 25-29
18. Fidler IJ, Gersten DM and Hart IR (1978) The biology of cancer invasion and metastasis. Adv Cancer Res 28: 149-150
19. Friess H, Yamanaka Y, Büchler MW, Ebert M, Beger HG, Gold LI and Korc M (1993a) Enhanced expression of transforming growth factor B isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105: 1846-1856
20. Friess H, Yamanaka Y, Büchler MW, Beger HG, Kobrin MS, Baldwin RL and Korc M (1993b) Enhanced expression of the type II transforming growth factor-beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 53: 2704-2707
21. Friess H, Yamanaka Y, Kobrin MS, Do AD, Büchler MW and Korc M (1995) Enhanced erbB-3 expression in human pancreatic cancer correlates with tumour progression. Clin Cancer Res 1: 1413-1420
22. Friess H, Berberat P, Schilling M, Kunz J, Korc M and Büchler MW (1996) Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. J Mol Med 74: 35-42
23. Gress TM, Müller-Pillasch F, Lerch MM, Friess H, Büchler M and Adler G (1995) Expression and in situ localization of genes coding for extracellular matrix proteins and extracellular matrix proteases in pancreatic cancer. Int J Cancer 62: 407-413
24. Gudjonsson B (1987) Cancer of the pancreas: 50 years of surgery. Cancer 60: 2284-2303
25. Hull PA, Hughes CM, Staddon SL, Richman PI, Gullick WJ and Lemoine NR (1990) The c-erbB-2 proto-oncogene in human pancreatic cancer. J Pathol 161: 195-200
26. He CJ, Rebibou JM, Peraldi MN, Meulders Q and Rondeau E (1991) Growth factor-like effect of urokinase-type plasminogen activator in human renal cells. Biochem Biophys Res Commun 176: 1408-1416
27. Jankum J, Merrick H and Goldblatt PJ (1993) Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers J Cell Biochem 53: 135-144
28. Kobrin MS, Yamanaka Y, Friess H, Lopez ME and Korc M (1993) Aberrant expression of the type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res 53: 4741-4744
29. Kohga S, Harvey SR, Suzumiya J, Sumiyoshi A and Markus G (1989) Comparison of the immunohistochemical localisation of urokinase in normal and cancerous human colon tissue. Fibrinolysis 3: 17-22
30. Korc M, Chandrasekar B, Yanianaka Y, Friess H, Büchler MW and Beger HG (1992) Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increase in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 90: 1352-1360
31. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V and Garbisa S (1981) Effect of plasminogen activator, plasmin and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 41: 4629-4636
32. Ossowski L, Russo-Payne H and Wilson EL (1991) Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumour in the nude mouse. Cancer Res 51: 274-281
33. Pedersen H, Grondahl-Hansen J, Francis D, Osterlind K, Hauser HH, Dano K and Brünner N (1994) Urokinase and plasminogen activator inhibitor type I in pulmonary adenocarcinoma. Cancer Res 54: 120-123
34. Pyke C, Kristensen P, Ralfkiaer E, Grondal-Hansen J, Eriksen J, Blasi F and Dano K (1991) Urokinase-type plasminogen activator is expressed in stromal cells and its receptor at invasive loci in human colon adenocarcinomas. Am J Pathol 138: 1059-1067
35. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, Appella E and Blasi F (1990) Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9: 467-474
36. Saeki T, Stromberg K, Qi CF, Gullick WJ, Tahara E, Normanno N, Ciardiello F, Kenney N, Johnson GR and Salomon DS (1992) Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumours. Cancer Res 52: 3467-3473
37. Schmalfeldt B, Kuhn W, Reuning U, Pache L, Deltmar P, Schmitt M, Jänicke F, Höfler H and Graeff H (1995) Primary tumour and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res 55: 3958-3963
38. Schmitt M, Jänicke F and Graeff H (1992) Tumour associated proteases. Fibrinolysis 6: 3-26
39. Takai S, Yamamura M, Tanaka K, Kawanishi H, Tsuji M, Nakane Y, Hioki K and Yamamoto M (1991) Plasminogen activators in human gastric cancers correlation with DNA ploidy and immunohistochemical staining. Int J Cancer 48: 29-27
40. Takeuchi Y, Nakao A, Harada A, Nonamy T, Fukatsu T and Takagi H (1993) Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Am J Gastroenterol 88: 1928-1933
41. Vassalli J-D, Sappino AP and Belin D (1991) The plasminogen activator/plasmin system. J Clin Invest 88: 1067-1072
42. Verde P, Stoppelli MP, Galeffi P, DiNocera P and Blasi F (1984) Identification and primary sequence of an unspliced human urokinase poly(A)+ RNA. Proc Natl Acad Sci USA 81: 4727-4731
43. Yamanaka Y, Friess H, Büchler MW, Kobrin MS, Beger HG and Korc M (1993a) Coexpression of epidermal growth factor receptor and its ligands is associated with enhanced aggressiveness of human pancreatic cancer. Anticancer Res 13: 565-570
44. Yamanaka Y, Friess H, Büchler MW, Beger HG, Uchida E, Masahiko O, Kobrin MS and Korc M (1993b) Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumour stage. Cancer Res 53: 5289-5296
45. Yamanaka Y, Friess H, Büchler MW, Kobrin MS, Kunz J, Beger HG and Korc M (1993c) Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Human Pathol 24: 1127-1134
46. Yokoyama M, Ebert M, Funatomi H, Friess H, Büchler MW, Johnson GK and Korc M (1995a) Amphiregulin is a potent mitogen in human pancreatic cancer cells: correlation with patients' survival. Int J Oncol 6: 625-631
47. Yokoyama M, Funatomi H, Kobrin MS, Ebert M, Friess H, Büchler MW and Korc M (1995b) Betacellulin, a member of the epidermal growth factor family, is overexpressed in human pancreatic cancer. Int J Oncol 7: 825-829